Experts and Doctors on antineoplastic agents in Germany

Summary

Locale: Germany
Topic: antineoplastic agents

Top Publications

  1. Sasaki T, Larsson H, Tisi D, Claesson Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol. 2000;301:1179-90 pubmed
    ..Together, these data indentify endostatin-XV as an angiogenesis inhibitor, which differs from endostatin-XVIII in several important functional details. ..
  2. Morgera S, Klonower D, Rocktäschel J, Haase M, Priem F, Ziemer S, et al. TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients?. Nephrol Dial Transplant. 2003;18:1361-9 pubmed
    ..Due to the high protein loss in haemofiltration, dialysis in combination with balanced protein substitution seems to be a suitable approach for clinical trials. ..
  3. Muthing J, Meisen I, Kniep B, Haier J, Senninger N, Neumann U, et al. Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J. 2005;19:103-5 pubmed
    ..This strict binding specificity of rViscumin and the increased expression of CD75s gangliosides in various tumors suggest this anticancer drug as a promising candidate for an individualised adjuvant therapy of human tumors. ..
  4. Butzke D, Hurwitz R, Thiede B, Goedert S, Rudel T. Cloning and biochemical characterization of APIT, a new l-amino acid oxidase from Aplysia punctata. Toxicon. 2005;46:479-89 pubmed
    ..Strongest homology exists to escapin, aplysianin A precursor, the cyplasins L and S and achacin. ..
  5. Scholz S, Kurauchi K, Kinoshita M, Oshima Y, Ozato K, Schirmer K, et al. Analysis of estrogenic effects by quantification of green fluorescent protein in juvenile fish of a transgenic medaka. Environ Toxicol Chem. 2005;24:2553-61 pubmed
  6. Schrama D, Reisfeld R, Becker J. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5:147-59 pubmed
    ..Here, we discuss recent preclinical and clinical data for antibody-drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes. ..
  7. Wilop S, Crysandt M, Bendel M, Mahnken A, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie. 2008;31:665-70 pubmed publisher
  8. Staehler M, Haseke N, Schöppler G, Stadler T, Karl A, Siebels M, et al. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res. 2008;13:531-5 pubmed
    ..Metastasectomy either had no influence on the course of disease. Anti-angiogenetic therapy with sunitinib treatment was not effective, possibly related to a low vascular density (CD31 expression) in CDC. ..
  9. Hölscher G, Anthuber C, Bastert G, Burges A, Mayr D, Oberlechner E, et al. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up. Acta Obstet Gynecol Scand. 2009;88:440-8 pubmed publisher
    ..There is no evidence for any benefit of adjuvant chemotherapy. Surgery remains the cornerstone of treatment, yet the benefit of postoperative therapy is still under debate. ..

More Information

Publications493 found, 100 shown here

  1. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009;8:73-9 pubmed
    ..Based on the number of reports in the literature, new drugs that most frequently cause IHA are the new generation of cephalosporins, diclofenac, oxaliplatin and fludarabin. ..
  2. Hartmann J, Haap M, Kopp H, Lipp H. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10:470-81 pubmed
  3. Salama A. Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol. 2011;4:107-18 pubmed publisher
    ..Thus, the need for a specific therapy is essential, and the ultimate solution is to clarify and halt the mechanism(s) that lead to the development of ITP. ..
  4. Tribius S, Ihloff A, Rieckmann T, Petersen C, Hoffmann M. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett. 2011;304:71-9 pubmed publisher
  5. Jadulco R, Edrada R, Ebel R, Berg A, Schaumann K, Wray V, et al. New communesin derivatives from the fungus Penicillium sp. derived from the Mediterranean sponge Axinella verrucosa. J Nat Prod. 2004;67:78-81 pubmed
    ..All structures were unambiguously established by 1D and 2D NMR and MS data. In several bioassays performed on different leukemia cell lines, the communesins exhibited moderate antiproliferative activity. ..
  6. Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte M, et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun. 2004;321:403-12 pubmed
    ..We further demonstrate an rViscumin-mediated, HER-2-dependent down-regulation of bcl-2 and the dose-dependent activation of members of the MAPK family, p42/44, SAPK/JNK, and p38, but not of caspases-3 and -7. ..
  7. Schuette W, Blankenburg T, Schneider C, von Weikersthal L, Guetz S, Laier Groeneveld G, et al. Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006;8:135-9 pubmed
    ..Gemcitabine/carboplatin is a convenient and effective treatment for advanced-stage non-small-cell lung cancer (NSCLC), but modification of the schedule to diminish thrombocytopenia is worthwhile...
  8. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 2010;28:166-71 pubmed publisher
    ..Treatment of pancreatic cancer cells with curcumin resulted in an induction of apoptosis. The results indicate that curcumin inhibits several key factors in cancer cellular pathways and may be of interest in pancreatic cancer. ..
  9. Dihazi H, Dihazi G, Jahn O, Meyer S, Nolte J, Asif A, et al. Multipotent adult germline stem cells and embryonic stem cells functional proteomics revealed an important role of eukaryotic initiation factor 5A (Eif5a) in stem cell differentiation. J Proteome Res. 2011;10:1962-73 pubmed publisher
    ..Our data highlights the important role of Eif5a and its hypusination for stem cell differentiation and proliferation. ..
  10. Vasko R, Mueller G, von Jaschke A, Asif A, Dihazi H. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis. Eur J Pharmacol. 2011;670:50-7 pubmed publisher
    ..The involvement of these proteins in cisplatin resistance and their potential as therapeutic targets requires further evaluation. ..
  11. Wegert J, Bausenwein S, Kneitz S, Roth S, Graf N, Geissinger E, et al. Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro. Mol Cancer. 2011;10:136 pubmed publisher
    ..In vitro testing of primary tumor cultures provided clear evidence of a potential utility of retinoids in Wilms tumor treatment based on the analysis of gene expression, proliferation, differentiation and apoptosis. ..
  12. Korfel A, Elter T, Thiel E, Hänel M, Mohle R, Schroers R, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98:364-70 pubmed publisher
    ..The protocol assessed proved feasible and highly active with long-lasting remissions in a large proportion of patients. (ClinicalTrials.govIdentifier NCT01148173). ..
  13. Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F, et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res. 2014;323:131-43 pubmed publisher
    ..This validates the approach to use 3D cell culture screening systems to identify substances that would not be detectable by 2D based screening in otherwise similar culture conditions. ..
  14. Komyod W, Bohm M, Metze D, Heinrich P, Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res. 2007;5:271-81 pubmed
    ..However, in situ analysis of human melanoma specimens revealed SOCS3 immunoreactivity in 3 out of 10 samples, suggesting that in vivo SOCS3 may possibly play a role in IL-6 resistance in at least a fraction of tumors. ..
  15. Distler U, Souady J, Hülsewig M, Drmić Hofman I, Haier J, Denz A, et al. Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. Mol Cancer Ther. 2008;7:2464-75 pubmed publisher
    ..Consequently, if an enhanced expression is existent in malignant tissues, we propose the targeting of CD75s-gangliosides with rViscumin as a novel potential strategy in adjuvant treatment of pancreatic malignancies. ..
  16. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, et al. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol. 2009;266:1291-300 pubmed publisher
    ..Due to a slight increase of relevant late dysphagia, functional outcome regarding swallowing and tracheotomy free breathing should be more focused in future larynx organ preservation trials...
  17. Goltz J, Schmid J, Ritter C, Knödler P, Petritsch B, Kirchner J, et al. Identification of risk factors for catheter-related thrombosis in patients with totally implantable venous access ports in the forearm. J Vasc Access. 2012;13:79-85 pubmed publisher
    ..To identify risk factors for the development of catheter-related thrombosis (CRT) in patients with totally implantable venous access ports (TIVAP) in the forearm, and to analyze the effect of prophylaxis and treatment...
  18. Kniess T. Radiolabeled small molecule inhibitors of VEGFR - recent advances. Curr Pharm Des. 2012;18:2867-74 pubmed
    ..It is covering aspects of the radiosynthesis as well the results of radiopharmacological and biological evaluation. ..
  19. Baumgarten P, Brokinkel B, Zinke J, Zachskorn C, Ebel H, Albert F, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol. 2013;28:1157-66 pubmed publisher
    ..Further investigations are needed to study the response to drugs targeting the VEGF pathway in relation to the expression profile of VEGF and its receptors in high grade meningiomas. ..
  20. Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta Yepez S. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol. 2016;97:275-90 pubmed publisher
    ..Finally, we comparatively summarize the next generations of anti CD20 monoclonal antibodies to highlight their advantages relative to their ancestor: Rituximab. ..
  21. Schadendorf D, Larkin J, Wolchok J, Hodi F, Chiarion Sileni V, Gonzalez R, et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80-91 pubmed publisher
    ..The finding that the difference in grade 3/4 AEs between the arms did not translate into clinically meaningful differences in the reported HRQoL may be relevant in the clinical setting. NCT01844505. ..
  22. Soler M, Stoeva S, Voelter W. Complete amino acid sequence of the B chain of mistletoe lectin I. Biochem Biophys Res Commun. 1998;246:596-601 pubmed
    ..These results are of crucial importance in order to understand the biological activity of ML-1...
  23. Kolb H. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang. 1998;74 Suppl 2:321-9 pubmed
    ..The mechanism of the graft-versus-leukemia reaction is discussed. ..
  24. Mertens R, Brost H, Granzen B, Nowak Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr. 1999;158 Suppl 3:S154-8 pubmed
    ..AT supplementation constitutes a good alternative treatment of severe VOD in comparison with other thrombolytic therapies, particularly in patients at high risk of bleeding. ..
  25. Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol. 2003;70:1-10 pubmed
    ..In conclusion, the qPCR protocol used in this study is a reliable and fast method for monitoring molecular response in CML. ..
  26. Van Valen F, Fulda S, Schafer K, Truckenbrod B, Hotfilder M, Poremba C, et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer. 2003;107:929-40 pubmed
  27. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W, et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood. 2005;106:3958-61 pubmed
    ..Our data show that the addition of kinase inhibitors to conventional chemotherapy might be a new therapeutic option for CBF-AML expressing mutant KIT. ..
  28. Alt A, Lammens K, Chiocchini C, Lammens A, Pieck J, Kuch D, et al. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta. Science. 2007;318:967-70 pubmed
    ..Our analysis reveals the set of structural features that enable Pol eta to replicate across strongly distorting DNA lesions. ..
  29. Garmann D, Warnecke A, Kalayda G, Kratz F, Jaehde U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J Control Release. 2008;131:100-6 pubmed publisher
    ..Macromolecular platinum complexes specially designed to circumvent reduced cellular accumulation may be a promising approach to overcome cisplatin resistance. ..
  30. Bran B, Bran G, Hormann K, Riedel F. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol. 2009;34:255-61 pubmed
  31. Elter T, Stipanov M, Heuser E, von Bergwelt Baildon M, Bloch W, Hallek M, et al. Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?. Int J Hematol. 2009;90:199-204 pubmed publisher
    ..Furthermore, this study was initiated as the groundwork for a large phase III randomised trial. ..
  32. Wenzel N, Chavain N, Wang Y, Friebolin W, Maes L, Pradines B, et al. Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. J Med Chem. 2010;53:3214-26 pubmed publisher
    ..Altogether, these dual drugs seem to be more appropriate to be developed as antiproliferative agents against mammalian cancer cells than Plasmodium parasites...
  33. Jacobs V, Mayer S, Paessens B, Bernard R, Harbeck N, Kiechle M, et al. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer. Onkologie. 2011;34:614-8 pubmed publisher
    ..The main reasons are asymmetrical costs for this FN low-risk pBC group. These results emphasize the importance of correct medical coding to avoid potential losses. ..
  34. Gruber W, Hutzinger M, Elmer D, Parigger T, Sternberg C, Cegielkowski L, et al. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget. 2016;7:7134-48 pubmed publisher
    ..The results support the use of DYRK1B antagonists for the treatment of HH/GLI-associated cancers where SMO inhibitors fail to demonstrate therapeutic efficacy. ..
  35. Steinmetz H, Herbertz A, Bertram M, Diehl V. Increase in interleukin-6 serum level preceding fever in granulocytopenia and correlation with death from sepsis. J Infect Dis. 1995;171:225-8 pubmed
    ..Median level was 7253 pg/mL (range, 445-95,906) within 3 days of death. Determination of IL-6 may be useful for early assessment and as a prognostic tool in leukocytopenic fever. ..
  36. Rudolf R, Salm T, Rustom A, Gerdes H. Dynamics of immature secretory granules: role of cytoskeletal elements during transport, cortical restriction, and F-actin-dependent tethering. Mol Biol Cell. 2001;12:1353-65 pubmed
    ..In a late phase of maturation, 60% of secretory granules were found to be immobile and about half of these underwent F-actin-dependent tethering. ..
  37. Lage H, Dietel M. Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol. 2000;1:169-75 pubmed
    ..Although the role of BCRP in drug resistance of clinical cancers is still unclear, preliminary data obtained by mRNA and protein expression analyses support the assumption that it has a role in clinical multidrug resistance...
  38. Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, et al. NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Arch Surg. 2002;386:570-4 pubmed
    ..01). We could show that in unresectable advanced pancreatic cancer, NSC-631570 alone and in combination with gemcitabine nearly doubled the median survival times in patients suffering from advanced pancreatic cancer. ..
  39. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer. 2002;95:1045-50 pubmed
  40. Eich H, Muller R, Micke O, Kocher M, Berthold F, Hero B. Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?. Strahlenther Onkol. 2005;181:378-84 pubmed
    ..Chemotherapy appears to improve resectability, EFS, and OS. Radiotherapy is an integral part in the management of children and young adolescents with ENB in Kadish stage B and C. ..
  41. Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer Oppermann F. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer. 2006;94:203-7 pubmed
    ..Determination of MTHFR C677T and TS tandem repeat polymorphism has no predictive value...
  42. Habermehl D, Kammerer B, Handrick R, Eldh T, Gruber C, Cordes N, et al. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer. 2006;6:14 pubmed
    ..The potent proapoptotic effects of Ukrain are not due to the suggested "Ukrain-molecule" but to the cytotoxic efficacy of Chelidonium majus L. alkaloids including chelidonine. ..
  43. Nauck M, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, et al. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab. 2007;92:1600-5 pubmed
    ..Hypoglycemia did not recur despite discontinuation of GH/glucocorticoid treatment. Our findings are compatible with a new form of tumor hypoglycemia caused by circulating tumor-derived IGF-I. ..
  44. Smollich M, Wülfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol. 2007;5:239-48 pubmed
    ..Targeting the ET axis via ET(A)R or ECE blockade seems to be a promising approach in the treatment of female malignancies. ..
  45. Schrader A, Seger M, Konrad L, Olbert P, Hegele A, Hofmann R, et al. Clinical impact of MDR1-expression in testicular germ cell cancer. Exp Oncol. 2007;29:212-6 pubmed
    ..However, as there was a clear trend, a larger number of patients suffering from metastatic non-seminomas should be studied, as MDR1 expression might have significant prognostic value in this particular subgroup of patients. ..
  46. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn L, et al. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer. 2008;98:1525-32 pubmed publisher
    ..The suboptimal effect of trastuzumab compared to the maximally possible effect induced by ATc demonstrates a high potential for improved ERBB2 blocking therapies. ..
  47. Michaelis M, Bliss J, Arnold S, Hinsch N, Rothweiler F, Deubzer H, et al. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res. 2008;14:6531-7 pubmed publisher
    ..EGFR-targeted cytotoxic reagents such as scFv(14E1)-ETA and TGF-alpha-ETA represent promising candidates for further development as antineuroblastoma agents, especially in combination with cisplatin. ..
  48. Boeck S, Metzeler K, Hausmann A, Baumann A, Gallmeier E, Parhofer K, et al. Cisplatin-based chemotherapy for pulmonary metastasized germ cell tumors of the testis--be aware of acute respiratory distress syndrome. Onkologie. 2009;32:125-8 pubmed publisher
    ..Further clinical research in order to better define risk factors for developing ARDS in this patient population as well as novel strategies for the prevention and treatment of ARDS in those patients are necessary. ..
  49. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem. 2009;10:1145-8 pubmed publisher
    ..This communication explores the concept of inhibiting Plk1 with a small-molecule inhibitor of the protein-protein interactions required for Plk1 function. ..
  50. Lehrnbecher T, Schubert R, Behl M, Koenig M, Rose M, Koehl U, et al. Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia. Br J Haematol. 2009;147:700-5 pubmed publisher
    ..Therefore, effective prevention, including chemoprophylaxis and active immunization, has to be considered in this patient population. ..
  51. Meyer M, Rübsamen D, Slany R, Illmer T, Stabla K, Roth P, et al. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS ONE. 2009;4:e7768 pubmed publisher
    ..The data also support the notion that the therapeutic success of cytotoxic drugs may depend on their ability to promote the differentiation of tumor-initiating cells. ..
  52. Dempke W, Heinemann V. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer Res. 2010;30:4673-7 pubmed
    ..These studies may enable further establishment of the correlation between K-ras mutations and resistance to cetuximab and panitumumab in CRC patients. ..
  53. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686-92 pubmed publisher
    ..The score can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention. ..
  54. Hegele A, Heinzer H, Ruttinger D, Siebels M. [DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?]. Aktuelle Urol. 2012;43:219-26 pubmed
  55. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;11:CD008079 pubmed publisher
    ..The available evidence regarding the other assessed comparisons was not sufficient to deduct final conclusions. ..
  56. Klein R, Kellermeier M, Touraud D, Müller E, Kunz W. Choline alkylsulfates--new promising green surfactants. J Colloid Interface Sci. 2013;392:274-280 pubmed publisher
    ..Taken together, our findings highlight that the harmless green cation choline is of great potential for the design of new surfactants. ..
  57. Meneses Lorente G, McIntyre C, Hsu J, Thomas M, Jacob W, Adessi C, et al. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab. Cancer Chemother Pharmacol. 2017;79:1239-1247 pubmed publisher
    ..The dose and schedule of lumretuzumab were optimised for concomitant therapy at doses substantially below the highest dose investigated. ..
  58. Honig A, Rieger L, Kristen P, Eck M, Frambach T, Tschammler A, et al. A case of metastasizing invasive hydatidiform mole. Is less--less good? Review of the literature with regard to adequate treatment. Eur J Gynaecol Oncol. 2005;26:158-62 pubmed
    ..Without respect to histology "high-risk" cases are recommended to obtain polychemotherapy...
  59. Hartmann J. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs. 2007;18:245-54 pubmed
  60. Labanaris A, Zugor V, Smiszek R, Nützel R, Kühn R. Anaplastic sarcoma of the kidney. ScientificWorldJournal. 2009;9:97-101 pubmed publisher
    ..We present a case of a new tumor entity of the kidney, namely the anaplastic sarcoma of the kidney, a tumor of high malignancy. ..
  61. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567-71 pubmed publisher
    ..Together, sorafenib monotherapy before or after allo-SCT has remarkable clinical activity in poor risk FLT3-ITD-positive AML and deserves further evaluation in prospective clinical trials. ..
  62. Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski I, Macdonald T, et al. REST is a novel prognostic factor and therapeutic target for medulloblastoma. Mol Cancer Ther. 2012;11:1713-1723 pubmed publisher
    ..A REST-dependent decrease in cell growth was also observed following SAHA treatment. Thus, our studies suggest that HDACIs may have therapeutic potential for patients with REST-positive tumors. This warrants further investigation. ..
  63. Schmitz N, Prange E, Haferlach T, Griesser H, Sonnen R, Schlegelberger B, et al. High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Bone Marrow Transplant. 1991;8:503-6 pubmed
    ..We report the first patient with relapsed AILD successfully treated by HDCT and ABMT. This 21-year-old male is alive and free of disease 27 months after ABMT with a Karnofsky score of 100%. ..
  64. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 2001;12:459-65 pubmed
    ..Importantly, cell growth of fibroblasts was only very weakly affected by treatment with pamidronate. These results suggest that pamidronate may be a useful agent for the treatment of patients with osteosarcoma. ..
  65. Knobbe C, Merlo A, Reifenberger G. Pten signaling in gliomas. Neuro Oncol. 2002;4:196-211 pubmed
    ..Furthermore, the possibility of selective targeting of PTEN mutant tumor cells by specific pharmacologic inhibitors of members of the Pten/PI3K/Akt pathway opens up new perspectives for a targeted molecular therapy of malignant gliomas. ..
  66. Kaiser R, Tremblay P, Sezer O, Possinger K, Roots I, Brockmoller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics. 2004;14:271-8 pubmed
    ..Polymorphisms and haplotype analysis of the 5-HT3A receptor gene may not serve as a pharmacogenetic predictor of the antiemetic treatment with 5-HT3 receptor antagonists in cancer patients. ..
  67. Doering M, Ba L, Lilienthal N, Nicco C, Scherer C, Abbas M, et al. Synthesis and selective anticancer activity of organochalcogen based redox catalysts. J Med Chem. 2010;53:6954-63 pubmed publisher
    ..Overall, the high efficacy and selectivity of (redox) catalytic sensor/effector compounds warrant further, extensive testing toward transfer into the clinical arena. ..
  68. Moreno Villanueva M, Eltze T, Dressler D, Bernhardt J, Hirsch C, Wick P, et al. The automated FADU-assay, a potential high-throughput in vitro method for early screening of DNA breakage. ALTEX. 2011;28:295-303 pubmed
    ..The main advantages of this assay are high reproducibility, easy handling, lack of operator bias, high-throughput, speed, and low cost. ..
  69. Heidenreich A, Rawal S, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human ?? integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prost. Ann Oncol. 2013;24:329-36 pubmed publisher
    ..The addition of intetumumab to docetaxel resulted in shorter PFS without additional toxicity among CRPC patients. ..
  70. Drechsler S, Bruntsch U, Eggert J, Grote Kiehn J, Gosse H, Bangerter M, et al. Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Support Care Cancer. 1997;5:387-95 pubmed
    ..3%) and tiredness (7.3%). Once-daily tropisetron+dexamethasone over several days is well tolerated and is a simple means of achieving further significant improvement in the efficacy of tropisetron against acute and delayed symptoms. ..
  71. Wenger F, Kilian M, Braumann C, Neumann A, Ridders J, Peter F, et al. Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer. Clin Exp Metastasis. 2002;19:169-73 pubmed
    ..8% after saline, in 37.5% after octreotide and in 0% after taurolidine irrigation (P < 0.05). Thus port site metastasis was effectively prevented by taurolidine irrigation after staging-laparoscopy in pancreatic cancer. ..
  72. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann J, Horwich A, Clemm C, et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer. 2004;91:683-7 pubmed
    ..In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care. ..
  73. Groll M, Schellenberg B, Bachmann A, Archer C, Huber R, Powell T, et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature. 2008;452:755-8 pubmed publisher
    ..It is thus possible that these bacteria are capable of producing proteasome inhibitors of the syrbactin class. ..
  74. Lünenbürger H, Lanvers Kaminsky C, Lechtape B, Frühwald M. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs. 2010;21:514-22 pubmed publisher
    ..Idarubicin or mitoxantrone represent potent alternatives to doxorubicin, and vinorelbine may substitute vincristine in future clinical trials. ..
  75. Chromik A, Daigeler A, Bulut D, Flier A, May C, Harati K, et al. Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res. 2010;29:21 pubmed publisher
    ..Our results indicate, that TRD is likely to provide multifaceted cell death mechanisms leading to a cell line specific diversity. ..
  76. Köberle B, Tomicic M, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta. 2010;1806:172-82 pubmed publisher
    ..The present review describes and discusses the clinical relevance of in vitro models by comparing the preclinical findings to data obtained in clinical studies. ..
  77. Rose A, Grandoch M, Vom Dorp F, Rubben H, Rosenkranz A, Fischer J, et al. Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol. 2010;160:1690-8 pubmed publisher
    ..This should be relevant for dosing regiments to optimize the treatment with this promising anti-tumour drug. ..
  78. Stock C, Ludwig F, Schwab A. Is the multifunctional Na(+)/H(+) exchanger isoform 1 a potential therapeutic target in cancer?. Curr Med Chem. 2012;19:647-60 pubmed
    ..Consequently, NHE1 including its regulators may represent potential targets in anticancer therapy. Different NHE1 inhibitors are compared and possible clinical exploitations of NHE1 inhibition are discussed. ..
  79. Borchmann P, Eichenauer D, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9:450-9 pubmed publisher
    ..Here, we focus on evidence from large clinical trials with solid conclusions. ..
  80. Weberschock T, Strametz R, Lorenz M, Rollig C, Bunch C, Bauer A, et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2012;:CD008946 pubmed publisher
    ..Larger studies with comparable, clearly-defined end points for all stages of mycosis fungoides, and a focus on safety, quality of life, and duration of remission as part of the outcome measures, are necessary. ..
  81. Buhrmann C, Shayan P, Popper B, Goel A, Shakibaei M. Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients. 2016;8:145 pubmed publisher
    ..Overall, our results demonstrate that resveratrol can suppress tumorigenesis, at least in part by targeting Sirt1 and suppression of NF-κB activation. ..
  82. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-46 pubmed publisher
    ..Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy. F Hoffmann-La Roche/Genentech Inc. ..
  83. Radhakrishnan H, Ilm K, Walther W, Shirasawa S, Sasazuki T, Daniel P, et al. MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers. Cancer Lett. 2017;403:231-245 pubmed publisher
    ..Altogether, we reveal a novel death receptor-mediated apoptosis regulatory mechanism by MACC1 in solid cancers through modulation of the STAT1/3-Mcl-1 axis. ..
  84. Bhatti I, Abhari B, Fulda S. Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells. Cancer Lett. 2017;405:63-72 pubmed publisher
    ..The discovery of this synergistic combination that is effective even when apoptosis is blocked has important implications for the development of new treatment strategies for B-cell NHL. ..
  85. Raguse J, Gath H, Oettle H, Bier J. Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int J Oral Maxillofac Surg. 2004;33:606-9 pubmed
    ..The patient received interferon alpha2a subcutaneously for 6 months. A slow but steady reduction of the tumour was observed, and pre-existing symptoms disappeared...
  86. Kübler H, van Randenborgh H, Treiber U, Wutzler S, Battistel C, Lehmer A, et al. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate. 2005;63:385-94 pubmed
    ..Although there are gaps between in vitro studies and clinical trials, the present findings provide useful information for the establishment of clinical protocols involving imatinib in hormone-refractory prostate cancer. ..
  87. Schwerdt G, Freudinger R, Schuster C, Weber F, Thews O, Gekle M. Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells. Toxicol Sci. 2005;85:735-42 pubmed
    ..We demonstrate that intact mitochondria are important to prevent cisplatin-induced apoptosis in MDCK-C7 cells and that acidic conditions can aggravate the toxic effects of cisplatin. ..
  88. Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92:1398-405 pubmed
    ..In conclusion, this study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-kit and PDGF-R. ..
  89. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller Brüsselbach S, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005;19:1774-82 pubmed
    ..Treatment with mTor inhibitors may thus be particularly effective in IM-sensitive patients, whereas Akt-pathway activation variably contributes to clinically overt IM resistance. ..
  90. Buchner T, Berdel W, Wörmann B, Schoch C, Haferlach T, Schnittger S, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol. 2005;56:247-59 pubmed
    ..This finding did not vary by age under or above 60 years. Given the actual median age in this disease being more than 60 years the adequate management of older age AML remains as the major challenge. ..
  91. Zuse A, Schmidt P, Baasner S, Böhm K, Muller K, Gerlach M, et al. 9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J Med Chem. 2006;49:7816-25 pubmed
    ..In competition experiments, the most active compounds strongly displaced radiolabeled colchicine from its binding site in the tubulin, showing IC50 values virtually 3- to 4-fold lower than that of colchicine...
  92. Mussi C, Schildhaus H, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res. 2008;14:4550-5 pubmed publisher
    ..Imatinib should not be used in a neoadjuvant intent in these patients, and molecular analysis of activating mutations is strongly recommended. ..